Cassava Sciences continues to push back on allegations of scientific misconduct around newly released trial data for their investigational Alzheimer’s drug simufilam. Early data…
Data on Cassava Sciences’ Alzheimer’s drug candidate, simufilam, found it was not only safe, but modified disease biomarkers at six months, and improved cognition…
Drugmaker Cassava believes its experimental Alzheimer’s therapy, which sent the company’s stock values surging with a recent phase 2 study announcement, could beat Biogen’s…
Bombshell exposé in Science magazine and follow-up reporting “make a mountain out of a molehill,” leading Alzheimer’s experts say. The media is reporting that…
Year in review: Here are 2021’s most watched videos from our LiveTalks with Alzheimer’s and dementia experts, advocates and families. As part of our…
Cassava responded this week to allegations of scientific fraud and misconduct. It remains unclear whether complaints will lead to an FDA investigation or delay…
Cassava Sciences CEO Remi Barbier discusses the company’s Alzheimer’s drug candidate, simufilam. Scientists are diversifying their approaches to finding an effective treatment for Alzheimer’s…